Please login to the form below

Not currently logged in

Genentech extends deal with Galapagos

Genentech has extended its drug discovery deal with Galapagos for a third time

Genentech, a member of the Roche Group, has extended its integrated contract drug discovery agreement with Galapagos' service division Argenta.

The agreement, which could be worth up to £21.5m (€23.4m), covers a number of drug discovery programmes that utilise Argenta's expertise in computer-aided drug design, medicinal chemistry, in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech.

The extended agreement also allows Genentech to continue placing projects directly into Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services. 

Dr Chris Newton, senior vice-president of services of Galapagos, said: “The possibility for Genentech to continue placing projects directly with BioFocus also speaks to the complementary expertise and technological capabilities that Argenta and BioFocus possess.”

It is the third extension since the agreement was announced in December 2005.

18th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....